La prevenzione secondaria dell'ictus ischemico: Lo studio sparcl

The importance of the Hypercholesterolemia in the pathogenesis of the cardiovascular pathology and also in the stroke is emphasized through a review of the numerous trials and studies on this topic, (4S: Scandinavian Simvastatin Survival Study; ASCOTT-LLA: Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm; CARE: Cholesterol And Recurrent Events and, particularly, the study SPARCL: Stroke Preventing Aggressive Reduction in Cholesterol Levels). SPARCL is based on the control of 4731 patients enrolled after a stroke (ischemic or haemorrhagic) or a TIA dated of no more of 6 months. 2365 patients have been randomized to assume 80 mg. diarily of atorvastatine and 2366 a placebo and all must applie the dietetic regime suggested by the american National Cholesterol Education Program. The Authors consider the SPARCL as the better and expose with some tables the details of the research. Those of 4731 pts in whom LDL levels appeared reduced of the 50% (37%) assumed 80 mg. of atorvastatine and the reduction of fatality to 5 years appeared of the 16%.